Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body's ...

Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...

For years scientists have suspected that the Epstein-Barr virus (EBV)—a type of herpesvirus that infects 94 percent of the ...

Fenebrutinib shows promise as the first BTK inhibitor for both RMS and PPMS, reducing relapses and slowing disability progression. The FENhance 2 study demonstrated fenebrutinib's efficacy over ...

Autolus Therapeutics plc is continuing its work to become a pioneering cell therapy company in the space of AD. Learn more ...

A wearable system that measures the brain's electrical activity can show how brain circuits are affected in people with MS, a ...

Aging and shifting hormone levels influence how MS changes over time, and the overlap of these factors during midlife can ...

Findings showed fenebrutinib significantly reduced relapses vs teriflunomide in RMS and was noninferior to ocrelizumab in slowing disability progression in PPMS. Topline data were announced from two ...

Roche Holding could be entering a new growth chapter after unveiling strong late-stage trial data for its multiple sclerosis ...

One of the most common viruses in the world could be the cause of lupus, an autoimmune disease with wide-ranging symptoms, ...

Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presented at 41st Congress of ECTRIMS - - Phase 2 CALLIPER Data Demonstrated ...

Discover how cladribine compares to S1P modulators in treatment-naive relapsing-remitting MS, keep reading to learn more.